Nozomu Machida

2.7k total citations
135 papers, 1.4k citations indexed

About

Nozomu Machida is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Nozomu Machida has authored 135 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Pulmonary and Respiratory Medicine, 83 papers in Oncology and 50 papers in Surgery. Recurrent topics in Nozomu Machida's work include Gastric Cancer Management and Outcomes (89 papers), Colorectal Cancer Treatments and Studies (44 papers) and Gastrointestinal Tumor Research and Treatment (33 papers). Nozomu Machida is often cited by papers focused on Gastric Cancer Management and Outcomes (89 papers), Colorectal Cancer Treatments and Studies (44 papers) and Gastrointestinal Tumor Research and Treatment (33 papers). Nozomu Machida collaborates with scholars based in Japan, United States and Germany. Nozomu Machida's co-authors include Narikazu Boku, Kentaro Yamazaki, Yusuke Onozawa, Tomohiro Nishina, Akira Fukutomi, Hirofumi Yasui, Akiko Todaka, Takahiro Tsushima, Shuichi Hironaka and Tomohiro Yamaguchi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Nozomu Machida

118 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nozomu Machida Japan	20	819	802	429	255	251	135	1.4k
Yasuhiko Nagano Japan	31	1.1k 1.4×	951 1.2×	1.2k 2.9×	473 1.9×	237 0.9×	104	2.5k
Masato Ozaka Japan	21	1.2k 1.4×	581 0.7×	525 1.2×	268 1.1×	103 0.4×	186	1.5k
F Sellner Austria	13	470 0.6×	485 0.6×	559 1.3×	110 0.4×	106 0.4×	34	1.1k
Jaihwan Kim South Korea	22	1.1k 1.3×	579 0.7×	685 1.6×	352 1.4×	50 0.2×	123	1.5k
John C. McAuliffe United States	14	326 0.4×	429 0.5×	408 1.0×	133 0.5×	346 1.4×	33	883
Yi‐Ming Shyr Taiwan	24	1.1k 1.3×	765 1.0×	1.1k 2.7×	183 0.7×	132 0.5×	99	1.8k
Ulrike Heger Germany	21	789 1.0×	471 0.6×	586 1.4×	203 0.8×	125 0.5×	48	1.3k
Yangsoon Park South Korea	20	475 0.6×	390 0.5×	301 0.7×	244 1.0×	72 0.3×	59	1.2k
Usha Malhotra United States	21	785 1.0×	615 0.8×	694 1.6×	120 0.5×	81 0.3×	66	1.6k
G.J. Poston United Kingdom	20	798 1.0×	226 0.3×	297 0.7×	442 1.7×	76 0.3×	46	1.3k

Countries citing papers authored by Nozomu Machida

Since Specialization

Citations

This map shows the geographic impact of Nozomu Machida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nozomu Machida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nozomu Machida more than expected).

Fields of papers citing papers by Nozomu Machida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nozomu Machida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nozomu Machida. The network helps show where Nozomu Machida may publish in the future.

Co-authorship network of co-authors of Nozomu Machida

This figure shows the co-authorship network connecting the top 25 collaborators of Nozomu Machida. A scholar is included among the top collaborators of Nozomu Machida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nozomu Machida. Nozomu Machida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Machida, Nozomu, Takehiro Okumura, Narikazu Boku, et al.. (2025). A phase 2 study of adjuvant chemotherapy with 5‐fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G). Cancer. 131(7). e35807–e35807. 1 indexed citations

Hama, Takashi, Shintaro Ishikawa, Kei Hayashi, et al.. (2025). Nivolumab Plus 5-Fluorouracil/Leucovorin+Oxaliplatin for Gastric Cancer With Severe Peritoneal Metastasis. Anticancer Research. 45(4). 1583–1592.

Kawakami, Hisato, Shigenori Kadowaki, Akitaka Makiyama, et al.. (2025). Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer. Journal of Clinical Oncology. 43(19). 2184–2195. 2 indexed citations

Kadowaki, Shigenori, Tomoyuki Otsuka, Keiko Minashi, et al.. (2025). An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study. Gastric Cancer. 28(5). 955–967.

Ooki, Akira, Kei Muro, Kazumi Nishino, et al.. (2024). Phase 1b study of futibatinib plus pembrolizumab with or without chemotherapy in patients with esophageal carcinoma: Updated results of antitumor activity.. Journal of Clinical Oncology. 42(16_suppl). 4047–4047.

Hirata, Makoto, Hiroto Narimatsu, Emi Yoshioka, et al.. (2024). A case of an unreported point mutation in promoter 1B of the adenomatous polyposis coli gene, which is responsible for gastric adenocarcinoma and proximal polyposis of the stomach. Clinical Journal of Gastroenterology. 17(4). 602–606. 1 indexed citations

Tokunaga, Masanori, Nozomu Machida, Junki Mizusawa, et al.. (2024). Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Gastric Cancer. 27(3). 580–589. 6 indexed citations

Sato, Shinya, Takashi Hama, Kunihiko Hayashi, et al.. (2023). 1562P Claudin 18.2 expression in resected gastric cancer. Annals of Oncology. 34. S874–S874. 3 indexed citations

Yamamoto, Shun, Kei Muro, Takashi Kojima, et al.. (2023). 1532P Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy. Annals of Oncology. 34. S861–S862. 4 indexed citations

10.

Hayashi, Kei, ITARU HASHIMOTO, Shinsuke Nagasawa, et al.. (2023). Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer. Anticancer Research. 43(6). 2831–2840.

11.

Morizane, Chigusa, Nozomu Machida, Yoshitaka Honma, et al.. (2023). 1203P Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213. Annals of Oncology. 34. S709–S709. 1 indexed citations

12.

Muro, Kei, Hisato Kawakami, Shigenori Kadowaki, et al.. (2023). 1513MO A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7). Annals of Oncology. 34. S852–S853. 10 indexed citations

13.

Kano, Kazuki, Takanobu Yamada, ITARU HASHIMOTO, et al.. (2022). Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab. Anticancer Research. 42(3). 1535–1540. 6 indexed citations

14.

Kawakami, Hisato, Shuichi Hironaka, Taito Esaki, et al.. (2021). An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers. 13(4). 805–805. 14 indexed citations

15.

Hironaka, Shuichi, Ryo Sadachi, Nozomu Machida, et al.. (2021). Association of renal function with the safety and efficacy of cisplatin plus S-1 therapy and docetaxel plus cisplatin plus S-1 therapy in patients with advanced gastric cancer: an exploratory analysis of JCOG1013. Japanese Journal of Clinical Oncology. 52(1). 14–23.

16.

Shimoyama, Ryo, Susumu Hijioka, Nobumasa Mizuno, et al.. (2020). Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study). Pancreatology. 20(6). 1183–1188. 7 indexed citations

17.

Kawakami, Takeshi, Nozomu Machida, Hirofumi Yasui, et al.. (2016). Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 78(4). 809–814. 28 indexed citations

18.

Kataoka, Kozo, Masanori Tokunaga, Junki Mizusawa, et al.. (2015). A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). Japanese Journal of Clinical Oncology. 45(11). 1082–1086. 36 indexed citations

19.

Hamauchi, Satoshi, Takahiro Tsushima, Akiko Todaka, et al.. (2015). Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy. Gastric Cancer. 19(3). 894–901. 5 indexed citations

20.

Komatsu, Yoshito, Takayuki Yoshino, Kentaro Yamazaki, et al.. (2013). Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Investigational New Drugs. 32(3). 473–480. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact